Clinical Fellowships
This grant funds one-year clinical fellowships to train physicians in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR) at U.S. academic institutions.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships)
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds may only be used for fellow salary and benefits.
Summary: Supports U.S. academic programs to train physicians in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR Amyloidosis).
Key Information: Applications must be submitted by ACGME-accredited institutions with active cardiology fellowship programs; funding is awarded to institutions, not individuals.
Description
Alnylam Pharmaceuticals offers Clinical Fellowships to support educational clinical programs within U.S. healthcare academic organizations, specifically focusing on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The goal is to mentor and advance the training of physicians in the diagnosis, treatment, and research of ATTR Amyloidosis, fostering multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. Funding is provided directly to eligible institutions—not individuals—to support one-year fellowship programs that include interdisciplinary team training, clinical and research engagement, and robust monitoring and assessment.
